The Effects of Different HIV Type 1 Strains on Human Thymic Function by Ye, Ping et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 18, Number 17, 2002, pp. 1239–1251
© Mary Ann Liebert, Inc.
The Effects of Different HIV Type 1 Strains 
on Human Thymic Function
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ABSTRACT
Studies of HIV-1-infected humans indicate that the thymus can be infected by HIV-1. In some of these pa-
tients, there is a significant CD41 T cell decline and a faster disease progression. This phenomenon is more
evident in pediatric patients who depend heavily on their thymus for generation of new T cells. We hypoth-
esize that HIV-1 causes T cell regenerative failure within the thymus, which has a profound impact on dis-
ease progression. Building on our established human thymopoiesis model, we include dynamic interactions
between different HIV-1 strains (R5 and X4) and thymocytes. Our results predict that thymic infection with
different HIV-1 strains induces thymic dysfunction to varying degrees, contributing to differences in disease
progression as observed in both HIV-1-infected children and adults. Thymic infection in children is more se-
vere than in adults, particularly during X4 infection. This outcome is likely due to both a higher viral load
and a more active thymus in pediatric patients. Our results also indicate that a viral strain switch from R5
to X4 induces further deterioration in thymopoiesis. We predict that both viral and host factors play key roles
in controlling thymic infection, including strain virulence and health status of the thymus.
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INTRODUCTION
HIV-1 DISEASE IS MARKED by progressive loss of CD41 Tcells leading to immunodeficiency and death usually due
to opportunistic infections. CD41 T cell decline in blood may
result from either a reduction in T cell production in the thy-
mus, altered T cell migration patterns, or a decrease in T cell
lifespan. We have previously explored the second and third hy-
potheses showing that altered lymphocyte circulation patterns
may contribute to the loss of CD41 T cells,1,2 as enhanced apop-
tosis of bystander cells and immune activation lead to increased
cell death.3–5 In this paper we focus on the first hypothesis,
namely the role of the thymus during HIV-1 infection.
The thymus is the primary lymphoid organ generating recent
thymic emigrants (RTE) to the periphery. T cell receptor exci-
sion circles (TREC) were recently developed as a marker for
RTE in humans.6,7 Clinical studies of HIV-1-infected children
and adults indicate that the thymus is affected by HIV-1-in-
duced morphological changes, including decrease in total thy-
mocyte numbers and enhanced involution.8–10 Decreases in
naive T cells and TREC concentrations are documented in both
HIV-1-infected pediatric and adult patients.6,11,12 Thymic dys-
function and early thymic involution have been associated with
rapid disease progression in a subset of infants infected peri-
natally with HIV-1.13–15
Mechanisms associated with thymic HIV-1 infection have
been extensively studied in several in vivo and in vitro systems,
including SCID-hu thy-liv mouse, human thymic organ culture,
thymocyte-epithelial cell culture, SIV/SHIV infection of non-
human primates, and FIV infection of felines. As background,
we summarize the results of these studies as follows. The HIV-
1 receptor, CD4, is expressed on nearly all thymocytes. Thus,
coreceptor expression becomes a determinant of HIV-1 entry.
CCR5 is detected at low levels on mature thymocytes, while
CXCR4 is detected at high levels on the surface of almost all
thymocytes.16–19 Thus it is not surprising that X4 viral strains
(that use the CXCR4 coreceptor) infect almost all thymocytes,
whereas R5 strains (that use the CCR5 coreceptor) infect only
mature thymocytes.16,20,21 The more cytopathic X4 strains
replicate faster and to higher levels, and also aggressively de-
stroy thymocytes, while the slowly replicating, noncytopathic
R5 strains initially trigger destruction of stromal cells, and then
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spread to thymocytes.20,22 These studies suggest that in vivo
coreceptor specificity and entry efficiency are critical determi-
nants of HIV-1 pathogenesis in the thymus.
We have previously published a mathematical model ex-
ploring the effect of thymic infection on the course of pedi-
atric AIDS disease progression.23 Our results indicate that
thymic infection can augment peripheral HIV-1 infection by
acting as a source of both virus and infected T cells. Here, we
construct a new mathematical model to illustrate the dynamic
interactions between different HIV-1 strains and relevant sub-
sets of thymocytes. We hypothesize that thymic infection with
either R5 or X4 strains causes thymic dysfunction, contribut-
ing to differences in disease progression as seen in both HIV-
1-infected children and adults. Underlying mechanisms in-
clude the pattern of coreceptor expression on thymocytes, the
virulence of viral strains, and the ability of thymocytes to sup-
port viral replication. To capture the role of the thymus in
children as well as thymus involution in adults, separate mod-
els have been generated to capture differences in pediatric and
adult patients. These virtual human models of thymic infec-
tion with HIV-1 serve as both quantitative and qualitative tools
to measure the contribution of the thymus to the peripheral T
cell pool under different viral strain infection scenarios, as
well as to explore the pathogenic dynamics of HIV-1 strains
on thymocytes.We can further apply these models to predict




The HIV-1 R5 strains use CCR5 as a coreceptor, and the X4
strains use CXCR4, while the R5X4 strains are able to use both
coreceptors with comparable efficiency.24 R5 is the most com-
monly transmitted strain, while X4 and (or) R5X4 strains evolve
as the dominant species in about 50% of patients.25,26 X4 and
R5X4 are generally more cytopathic and correlate with acceler-
ated disease progression.27,28 Our goal is to explore whether
thymic infection with HIV-1 R5 or X4 strains could explain var-
ied disease progression patterns in pediatric and adult patients.
A diagram of our model illustrating host cell and viral dy-
namics in the thymus is shown in Figure 1. This model is con-
structed based on our previous human thymopoiesis model.7 We
consider both the normal thymopoiesis process and infection of
thymocyte subsets by either R5 or X4 strains. Model equations,
variables, and parameters are discussed in the Appendix.
RESULTS
Virtual pediatric infection
Pediatric infection with HIV-1 occurs chiefly through trans-
mission from the mother during delivery or in late-stage preg-
nancy.29 Our model could account for prenatal infection, but
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FIG. 1. The model of thymic HIV-1 infection with R5 or X4 strains. Rectangles represent cell populations and ellipses repre-
sent viral populations. Cell dynamics are illustrated using solid lines and viral dynamics are illustrated using dashed lines. Five
uninfected thymocyte subsets are triple negative (TN), intrathymic T progenitor (ITTP), double positive (DP), CD4 single posi-
tive (SP4), and CD8 single positive (SP8) cells. SP4 and SP8 cells emigrate to the periphery as RTE. Added to normal healthy
thymopoiesis dynamics7 are infection and enhanced death of uninfected thymocytes. Three R5-infected cell subsets and four X4-
infected cell subsets are tracked: DPR, SP4R, SP8R, ITTPX, DPX, SP4X, and SP8X cells, respectively. They are generated by in-
fection and/or differentiation. Each of these infected cell populations differentiates, dies, and emigrates to the periphery. Two vi-
ral populations are tracked in the thymus: R5 and X4. Virus flows in from blood and is also produced by infected cells. Virus
also emigrates to the periphery and is cleared within the thymus.
we assume pediatric HIV-1 infection initiates at birth for sim-
plicity. One study indicates that TREC concentrations decline
fairly quickly after the onset of HIV-1 infection in infants.12
Thus we model HIV-1 infection occurring within the thymus
initiating at birth (i.e., birth 5 infection time 0), the same time
as newborns are infected with HIV-1.
We simulate total thymocytes and SP4/SP8 ratio in healthy,
uninfected individuals during the first 2 years of life as a con-
trol (solid lines, Fig. 2). Total thymocytes increase to their max-
imum at the age of one, then decline afterward (Fig. 2A). The
ratio of SP4/SP8 remains constant (Fig. 2B). During infection
with either R5 or X4 strains, total numbers of uninfected thy-
mocytes initially drop sharply, and then rebound and level off.
This is due to continual thymic growth in the first year of life.
After the first year, total uninfected thymocytes decrease, con-
sistent with thymic involution (Fig. 2A). HIV-1 infection within
the thymus reduces the number of SP4 cells to a greater extent
than SP8 cells, resulting in a decrease in the SP4/SP8 ratio (Fig.
2B). This is consistent with a remarkable depletion of SP4 cells
and a relative increase in SP8 cells as seen in studies of both
humans and SCID-hu mice.8,30,31 A decrease in the SP4/SP8
ratio likely contributes to the CD41/CD81 ratio inversion oc-
curring in the blood, a characteristic of HIV-1 infection.32
Thymic infection with X4 strains depletes total thymocytes and
decreases the SP4/SP8 ratio to a greater level as compared with
R5 infection.
Infection in the thymus establishes quickly and the number
of infected cells correlates with viral load within the thymus.
Infection with X4 occurs faster, and both viral load and the
number of infected cells are greater than during infection with
R5 (Fig. 2C and D). These results are similar to different in-
fection scenarios in the thymus of SCID-hu mice when inocu-
lated with R5 or X4 strains.16,20,22 One important model pre-
diction for children infected during the first year of life is that
X4 strain replication is enhanced due to growth of the thymus.
Thymic growth provides a greater number of X4 target cells
generating more infected thymocytes and higher viral load in
the thymus (Fig. 2C and D).
The rate of disease progression among HIV-1-infected chil-
dren varies greatly and the underlying mechanisms that deter-
mine this are not fully understood. Most pediatric patients fol-
low a disease progression pattern similar to that seen in adults,
except for a higher viral load.33 However, some infants infected
perinatally with HIV-1 develop AIDS very early in life and
have lymphocyte depletion pattern similar to infants born with
congenital absence or maldevelopment of the thymus known as
DiGeorge syndrome (characterized by very low levels of CD41,
CD81 T cells, and CD51 B cells).13,34 This group of infants
appears to have a peripheral blood immunophenotypic profile
corresponding to thymic dysfunction, likely caused by HIV-1.
Blood CD41 T cell data from Kourtis et al.13 representing 227
infants exposed to HIV-1 are presented in three settings: those
classified with a “thymic dysfunction profile” who have very
low CD41 T cell counts and faster disease progression (Fig.
3A, squares), those without the “thymic dysfunction profile”
who have low CD41 T cell counts and typical HIV-1 disease
progression patterns (Fig. 3A, circles), and uninfected controls
with normal CD41 T cell counts (Fig. 3A, triangles). Both vi-
ral and host factors have been implicated in those different pat-
terns.23
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FIG. 2. Virtual pediatric thymic HIV-1 infection. Two infection scenarios are simulated: infection with either R5 (dotted lines)
or X4 strains (dashed lines). A simulation of healthy, uninfected individuals serves as a control (solid lines). (A) The total unin-
fected thymocytes, (B) the SP4/SP8 ratio, (C) the total infected thymocytes by strain, and (D) the intrathymic viral load.
Our virtual infection model suggests that the bimodal pat-
tern of disease progression of pediatric patients may be ex-
plained by thymic infection with different viral strains. To test
this, we simulate the number of CD41 RTE exported per day
in three scenarios: healthy controls, patients infected with R5,
and patients infected with X4. To capture changes in blood
volume that occur over time in children, the rate of exported
CD41 RTE is divided by blood volume,7 to convert units to
cells/day/mm3 blood (Fig. 3B). Each of the model simulations
of CD41 RTE per day during health, R5 infection, and X4 in-
fection has the same overall pattern change in peripheral
CD41 T cells as compared to the clinical study of uninfected
children, HIV-1-infected children without thymic dysfunction,
and HIV-1-infected children with a thymic dysfunction pro-
file (Fig. 3).13 These graphic results cannot be superimposed
directly as the peripheral CD41 T cell count will be larger
than the number of CD41 RTE emigrating from the thymus
per day; however, their trends are clearly comparable. For ex-
ample, during R5 and X4 infection, the rates of production of
CD41 RTE decrease to 62 and 24%, respectively, of their 
normal values during the first year of life. These decreases 
are correlated with CD41 T cells in the blood, which decrease
to 60 and 17% of their normal values in children without
thymic dysfunction and with thymic dysfunction, respectively
(Fig. 3).
In newborns, the thymus serves to establish the peripheral T
cell pool by contributing the majority of newly generated T cells
to the blood-lymphoid system (represented by the number of
RTE).35 Thus, we believe the immunophenotypes shown in the
blood can reflect what occurs in the thymus in young children.
Our results indicate that a decrease in thymic output due to HIV-
1 infection induces differing levels of CD41 T cell decline in
the peripheral system. Therefore, the thymus plays a critical
role in regulating CD41 T cell homeostasis in newborns dur-
ing HIV-1 infection. This is likely a key mechanism contribut-
ing to different disease progression patterns observed in pedi-
atric patients. X4 strains may be especially relevant in children,
as their thymuses are active and CXCR4 is the predominant
coreceptor expressed on thymocytes.
Virtual adult infection
To consider a virtual adult thymic infection experiment, we
follow a procedure similar to that outlined for the pediatric
model above. The thymus of a 30-year-old person is used to
study virtual adult infection (i.e., age 30 5 infection time 0).
The maximal number of thymocytes in thymic epithelial space
(TES) and the cell source from the bone marrow are chosen to
reflect an adult at that age.7 Our model predicts that in a 30-
year-old person the number of total thymocytes is 18.5% of to-
tal thymocytes at age one (note that this calculation can be per-
formed for a person of any age).
The virtual model of adult infection indicates that the num-
ber of total uninfected thymocytes drops quickly during infec-
tion with either R5 or X4 strains (Fig. 4A). This is a result of
both infection and the normal thymic involution process. The
SP4/SP8 ratio decreases more slowly and to a lesser extent as
compared with pediatric infection (compare Fig. 2B with Fig.
4B). Total infected thymocytes correlate with intrathymic viral
load (Fig. 4C and D). A bimodal pattern of R5 or X4 infection
in adults is similar to pediatric infection. However, adult thymic
infection with X4 strains causes less detrimental effects as com-
pared with that of pediatric X4 infection (compare Figs. 2 and
4). Infection in adults with X4 after 1 year generates a 14.2-
fold greater number of infected thymocytes and 1.2-fold higher
intrathymic viral load as compared with R5 infection (Fig. 4C
and D). These ratios increase to 46.9-fold and 3.9-fold respec-
tively during pediatric infection (Fig. 2C and D). This suggests
that X4 strains are more destructive in children, which may re-
sult from higher viral loads and active thymopoiesis with pro-
portionately higher CXCR4 expression on thymocytes.
It has been shown that TREC concentrations are variable in
adults after primary HIV-1 infection.11 Our model results (Fig.
4) suggest that adult thymic infection with different viral strains
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FIG. 3. Simulations of CD41 RTE exported from the thymus predict CD41 T cell counts in blood of pediatric patients. (A)
Medians and ranges of CD41 T cell counts in three groups of children: an HIV-1-exposed uninfected cohort (triangles), an HIV-
1-infected cohort without thymic dysfunction (circles), and an HIV-1-infected cohort with a thymic dysfunction profile (squares).13
(B) Three model simulations of the number of CD41 RTE per day in healthy controls (solid lines) and during infection with ei-
ther R5 (dotted lines) or X4 (dashed lines) strains. The dynamics of blood CD41 T cells and simulations of CD41 RTE are cor-
related as seen by similar percentage reductions over time by infection type.
could explain this variation. Although the X4 (R5X4) strains
are rarely transmitted, primary infection with the X4 (R5X4)
strains have been observed, for example, in individuals ho-
mozygous and heterozygous for CCR5D32.36,37 Other factors,
such as immune system activation in response to HIV-1 infec-
tion, may also be relevant for interpreting TREC level varia-
tions.
We summarize our infection model results in Table 1 and
provide experimental data for comparison.38,39 In both pediatric
and adult patients, our model indicates that infection with dif-
ferent viral strains can explain varying degrees of thymic dys-
function. X4 strains are significantly more destructive to the
thymus as compared with R5. When comparing the same viral
strain thymic infection scenarios in children and adults, pedi-
atric infection is more severe than in adults, especially during
X4 infection. This is likely due to higher viral load and con-
tinual growth of the thymus providing more target cells in chil-
dren.
Recently, two primary HIV-1 isolates have been charac-
terized to infect cells only through cell surface CD8 mole-
cules.40 We performed experiments of direct infection of SP8
cells by either R5 or X4 strains using our virtual pediatric and
adult model, while fixing all other processes as before (data
not shown). If SP8 cells can be infected by HIV-1, our sim-
ulations indicate that intrathymic viral load and total infected
cells increase by approximately 50% during pediatric X4 in-
fection. However, direct infection of SP8 cells does not change
infection outcomes in pediatric or adult R5 infection (data not
shown). This is explained by the lower virulence of R5 strains.
Simulations of adult X4 infection show little change when SP8
cells are infected likely due to few target cells available in
adults (data not shown). These results lend further support to
THYMIC INFECTION WITH HIV-1 1243
FIG. 4. Virtual adult thymic HIV-1 infection. Two infection scenarios are simulated: infection with either R5 (dotted lines) or
X4 (dashed lines) strains. A simulation of healthy, uninfected individuals serves as a control (solid lines). (A) The total unin-
fected thymocytes, (B) the SP4/SP8 ratio, (C) the total infected thymocytes by strain, and (D) the intrathymic viral load.
TABLE 1. SIMULATION VALUES AT YEAR 2 OF VIRTUAL INFECTION COMPARED WITH EXPERIMENTAL DATA
Pediatric model Adult model
Ratio R5 X4 R5 X4 Data References
Exported cells in an infected individual 
(%) 63 32 63 36 10–60 6,11 (human)
Exported cells in a healthy individual
Infected thymocytes in an infected individual 
(%) 0.009 0.632 0.004 0.098 0.001–1 38,39 (monkey)
Total thymocytes in an infected individual 
SP4 in an infected individual 1.59 0.84 1.70 1.22 0.5 31 (SCID-hu mouse)
SP8 in an infected individual
the hypothesis that X4 strains are highly pathogenic in chil-
dren.
Viral strain switch in adults
Establishment of initial HIV-1 infection is believed to occur
with R5 strains in the majority of individuals.26 However, due
to viral mutation and evolution, the viral pool becomes more
heterogeneous with progressive disease. X4 (R5X4) strains are
dominant in about 50% of patients, and have been correlated
with greater CD41 T cell depletion.26–28 To explore the effects
of a viral strain switch on thymic infection, we alter the influx
of R5 and X4 viral strains from blood into the thymus to cap-
ture a viral strain switch occurring in the periphery. In this work,
we do not make any assumptions as to what induces this switch,
but only model the events after the switch occurs.
We simulate a viral strain switch from R5 to X4 occurring
6 months after infection in a 30-year-old person. We assume
the viral strain switch from R5 to X4 occurs over a period of
6 months based on a study of HIV-1-infected patients under-
going highly active antiretroviral therapy (HAART) who ex-
perienced a viral strain switch back from X4 to R5 that occurred
in 6 months on average.41 The strain switch invokes a quick
drop in total uninfected thymocytes and the SP4/SP8 ratio (Fig.
5A and B), approaching the level seen in X4-only infection (Fig.
4A and B). Both viral strains and the corresponding infected
cell populations are present after the switch. X4-infected thy-
mocytes are more than 100-fold higher than when compared
with R5-infected thymocytes, likely due to higher infection
rates for X4 strains (Fig. 5C). X4 strains are dominant strains
and their viral load is approximately 10-fold higher than R5
(Fig. 5D). Varying the start time of the switch results in simi-
lar outcomes (data not shown). Varying the duration that a
switch occurs induces curve changes during the switch period,
but the same end results are obtained (data not shown). A vi-
ral strain switch in children yields a pattern similar to that seen
in adults (data not shown). These results indicate that a viral
strain switch from R5 to X4 may further deteriorate thymic
function, contributing to CD41 T cell depletion and HIV-1 dis-
ease progression.
Both viral and host factors play determinant roles
HIV-1 infection within the thymus may lead to viral clear-
ance or steady-state viral levels. To identify elements that con-
trol different infection trajectories, we implement uncertainty
and sensitivity analyses for all parameters in this model (cf. ref.
42). Detailed methods for these analyses are discussed in the
Appendix. Our model reveals that changes in only certain pa-
rameters lead to different infection outcomes. We briefly sum-
marize them below.
First, the rate of viral influx from blood (sR, sX) greatly con-
trols infection outcome. Infection within the thymus occurs only
when the rate of viral influx is above a certain value. This find-
ing is supported by two recent clinical studies,6,12 suggesting
that thymic infection with HIV-1 can be controlled by halting
viral influx from blood. The half-saturation constant of the vi-
ral input (c4) governs the speed at which virus establishes in-
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FIG. 5. Simulations of viral strain switch from R5 to X4 occurring over a 6-month period after 6 months of thymic infection
in virtual adult patients. Arrows point to the time period when the viral strain switch occurs followed by the 6 month duration
to complete the switch. (A) The total uninfected thymocytes, (B) the SP4/SP8 ratio, (C) the total infected thymocytes by strain,
and (D) the intrathymic viral load.
fection within the thymus; the lower its value, the quicker 
infection is established in the thymus (data not shown).
Second, virulence of HIV-1 strains, represented by both in-
fection rates (b) and viral production rates (p), also govern in-
fection outcomes. If infection rates or viral production rates
reach critical values, the thymus remains infected even after vi-
ral influx from the blood is halted. This finding indicates that
control of viral replication within the thymus is especially im-
portant for more virulent strains. In our model, we assume that
X4 strains infect more thymocyte subsets, and these infected
thymocytes generate more virions per cell as compared with R5
infection. If viral influx from blood is depleted, R5 infection
within the thymus is not sustained, and the system moves to the
uninfected state. However, X4 infection within the thymus is
maintained when the rate of viral influx is zero, since a greater
number of virions are generated.
Finally, three half-saturation constants that control the stem
cell source from bone marrow (c1), maximal number of thy-
mocytes in the TES region (c2), and enhanced death of unin-
fected thymocytes (c3) represent the thymic response to HIV-
1 infection. Varying c1 directly affects the TN population, while
varying c2 and c3 affects all thymocyte populations. When these
three parameters are increased, the thymus resists adverse ef-
fects caused by HIV-1, such as reduced stem cells from bone
marrow (or reduced use of stem cells), accelerated thymus at-
rophy, and enhanced death of thymocytes. Taken together, these
results suggest that improving inherent thymic function is a vi-
able target to controlling infection beyond directly controlling
viral replication in both blood and thymus.
DISCUSSION
This study explores thymic infection with different HIV-1
strains and evaluates its potential impact on peripheral T cell
homeostasis. Our mathematical models demonstrate that dif-
ferent viral strains can induce thymic dysfunction to varying
degrees, which is supported by variations observed both clini-
cally and experimentally.13,20,22 Primary infection with X4
(R5X4) strains or an early viral strain switch from R5 to X4
(R5X4) aggressively destroys thymic function and exports a
greater amount of infected T cells and virus to the periphery.
Recent data suggest that the thymus might be a source of HIV-
1 latently infected cells by exporting these cells to the periph-
ery.43 Our model also indicates that thymic dysfunction accel-
erates HIV-1 disease progression, especially in pediatric
patients whose thymus is more active and whose immune sys-
tem has not yet fully developed.
Simulations of the number of CD41 RTE per day during X4
or R5 infection correlate with peripheral CD41 T cell counts
in HIV-1-infected children previously defined as having or not
a “thymic dysfunction” profile.13 Our model suggests that X4
infection induces a decrease in the rate of exported CD41 RTE,
which accounts for the low number of blood CD41 T cells in
children with “thymic dysfunction” profile. A study of HIV-1-
infected children with either R5 or X4 strains determined that
differences in the decrease of CD41 T cell counts and TREC
levels were mainly due to a lower production of new CD41 T
cells by the thymus.44 It was hypothesized that this occurred as
a consequence of the inhibitory effect of different viral strains
on thymic function, which is consistent with our modeling re-
sults.
Our model also demonstrates a decreased export rate of
CD81 RTE during either R5 or X4 infection (data not shown).
Our results are supported by experimental data showing that a
loss of naive CD81 T cells occurs at the same rate as the loss
of naive CD41 cells.45 For children with thymic dysfunction,
our model suggests a decrease in the exported rate of CD81
RTE is responsible for low counts of CD81 T cells. Both very
low CD41 and CD81 T cell counts in the periphery induce T
cell immunodeficiency and early progression of disease in chil-
dren with thymus dysfunction. For children without thymus
dysfunction, peripheral CD81 T cell numbers increase,13 even
with the decline of CD81 RTE as predicted by our model. This
is due to peripheral CD81 T cell proliferation, which usually
occurs in the early phase of HIV-1 infection.32,46 The expan-
sion of CD81 T cells compensates for the decrease of thymic
output. This suggests that CD81 RTE exported to the periph-
ery are still functional and can proliferate in response to anti-
gen stimulation. Proliferation of peripheral CD81 T cells may
also be strongly correlated with CD41 T helper cell function.
Our model suggests that differences between R5 and X4
strains can explain the different immunophenotypes in pediatric
patients and that thymic dysfunction in HIV-1-infected children
could be due to infection with X4 strains. Although viral phe-
notypes were not analyzed in the study of Kourtis et al.,13 one
study supports our hypothesis showing that children infected
with X4 strains have significantly lower numbers of both pe-
ripheral CD41 T cells and thymic production of new T cells as
compared with children infected with R5 strains.44 Vertical
transmission of R5X4 or X4 strains has also been observed in
HIV-1-infected pediatric patients.47,48 Certainly, additional
work will be necessary to characterize viral strains isolated from
thymus and other compartments in patients with thymic dys-
function. Further, thymic output constitutes the majority of
newly generated T cells in children, and only a small percent-
age of newly generated T cells is derived from peripheral pro-
liferation; this is in contrast to adults.35 Thus, treatment strate-
gies aimed at improving thymic function are especially
important for HIV-1-infected children.
Adult thymic infection has also been explored in this paper.
Several studies have shown that the adult thymus is still func-
tional in many individuals and can contribute new cells to the
peripheral T cell pool.49,50 Our model reveals that X4 strains
are more virulent than R5 strains during adult thymic infection
and can accelerate disease progression. Further, the decrease in
RTE during either R5 or X4 infection can explain the decrease
observed in TREC concentrations during primary infection.
Our model provides a virtual system with which to identify
key players controlling thymic infection outcomes. These key
players include viral influx from blood into the thymus, viral
replication abilities within the thymus, the number of progenitor
cells from bone marrow, and inherent thymic function. Our find-
ings suggest strategies aimed at improving thymic function dur-
ing HIV-1 treatment. Our model would likely predict that sup-
pression of peripheral viral load through HAART would greatly
benefit thymic function recovery. Thymic infection can also 
be controlled if certain treatment drugs are able to cross the
blood–thymus barrier to directly inhibit viral replication within the
thymus. In addition, our model predicts that treatment aimed at
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improving bone marrow function, improving inherent thymic
function such as recovery of stromal cell function, limiting
thymic inflammation, and normalizing the cytokine network
each would aid recovery as well (cf. ref. 50a).
Our work focuses on exploring factors related to HIV-1 dif-
ferential coreceptor utilization. R5 and X4 strains considered in
our model may also represent any two strains differing in thymic
tropism and virulence. One study has shown that thymus-de-
rived HIV-1 strains have a higher affinity for thymocytes than
clones isolated from other compartments, and further that their
genotypes and phenotypes are different.51 Apart from viral phe-
notypes, factors such as host susceptibility to specific strains or
host immune status may also explain varying degrees of thymic
dysfunction. X4 strains were undetectable in the blood of many
individuals with lower TREC levels, and some HIV-1-infected
individuals have normal levels of TREC.11 This evidence im-
plies that thymic function may be affected differently from per-
son to person by the same HIV-1 strains, or that only specific
strains can cross the blood–thymus barrier. Another possibility
is that TREC levels measured in peripheral blood mononuclear
cells (PBMC)11 may not represent thymic output correctly due
to the influence of peripheral T cell dynamics.7 The time of ver-
tical transmission may also be relevant for pediatric infection.
Prenatal infection with R5 strains would have a more severe
impact on CD41 T lymphocyte depletion than intrapartum in-




Five uninfected thymocyte subsets are defined as T repre-
senting TN cells, I representing ITTP cells, D representing DP
cells, S4 representing SP4 cells, and S8 representing SP8 cells.
The equations for these uninfected thymocyte subsets during
HIV-1 infection are as follows:
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The notations for variables and parameters in Eqs. (1)–(5)
relating with normal human thymopoiesis are discussed in our
previous paper.7 Thymocytes have a loss term representing di-
rect HIV-1 infection. Target cells are determined based on the
surface expression of HIV-1 receptor and coreceptor.16–18 ITTP
cells are directly infected by X4 strains and DP and SP4 cells
are directly infected by both R5 and X4 strains. Thymocyte loss
is also due to indirect mechanisms such as infection of stromal
cells,52,53 alteration of the cytokine network,54,55 and infection
of hemopoietic progenitor cells.56,57 Our model captures these
mechanisms as follows. First, the maximal number of thymo-
cytes in the TES region, k(t), is reduced in response to in-
trathymic viral load, since marked involution of the TES region
has been reported in HIV-1-infected individuals.8–10 Second,
uninfected thymocytes in multiple stages are induced into apop-
tosis, largely including uninfected cells.30,58 Thus in Eqs.
(1)–(5), each subset of thymocytes has an enhanced death term
to account for enhanced apoptosis. Third, the second term in
Eq. (1) represents the decrease in cell source from the bone
marrow, which correlates with viral load in the thymus. Here
we use intrathymic viral load to represent bone marrow viral
load, assuming viral load in these two compartments is corre-
lated. Another interpretation for this term is the reduced use of
cell source by the thymus, as thymic function determines the
recovery of normal T cell subsets after bone marrow trans-
plantation.59,60
Equations (6)–(8) represent the rate of change of R5-infected
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Thymocytes are activated during thymopoiesis, undergoing
proliferation, differentiation, and death.61 Thus, once thymo-
cytes are infected by HIV-1, we assume they are productively






















































fected to give rise to R5-infected DP and SP4 cells. R5-infected
DP cells continue to differentiate into R5-infected SP4 and SP8
cells. The presence of infected SP8 cells (which lack a CD4 re-
ceptor) is suggested by experimental data indicating that in-
fected thymocytes differentiate into mature, productively 
infected SP8 cells containing proviral DNA and are able to ex-
press viral RNA.62,63 Equations for rates of change for both R5-
infected SP4 and SP8 cells have loss terms representing emi-
gration to the blood. Each equation for an infected subset of
thymocytes also has a death term. It has been suggested that
loss of thymocytes is due to direct killing of infected thymo-
cytes, including syncytium formation, destruction of plasma
membrane during viral budding.64
The equation for the rate of change of R5 virus is:
5 sR(t) 1 pR1 d
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is the rate of viral influx from blood.
No literature indicates how and when HIV-1 migrates into the
thymus. It has been suggested that the decrease in TREC can
occur relatively early during HIV-1 infection in infants.12 A
progressive decline in TREC concentrations was seen in adults
soon after HIV-1 seroconversion.11 During primary HIV-1 in-
fection, both a wide dissemination of virus and seeding of lym-
phoid organs occur.65 Thus, we assume that virus gets into the
thymus during early primary infection.
It has been shown that the number of thymocytes positive
for viral RNA in SIV-infected rhesus monkeys correlates with
the level of serum antigen,39 suggesting intrathymic viral load
correlates with plasma viral load. In our virtual infection model,
we assume the rate of viral influx from blood, sR(t), reaches a
constant level after a period of time [Eq. (10)], since after peak-
ing during primary infection, plasma viral load is stably main-
tained for several years prior to progression to AIDS stage.65
In Eq. (9), the rate of change of R5 virus is increased by vi-
ral production from R5-infected DP, SP4, and SP8 cells, re-
spectively. Here we assume viral mutation does not occur in
the thymus so that R5-infected cells generate only R5 virus.
Loss of R5 virus is due to clearance within the thymus and em-
igration to the blood.
Equations (11)–(16) represent the rates of change of X4-in-
fected thymocyte subsets together with the rate of change of
the X4 strains. These equations are similar to those for the R5-
infected thymocyte subsets and R5 virus, with the exception
that X4 strains have one more target cell population, ITTP cells,
as they express high level of CXCR4. We also assume that R5
and X4 strains have similar access to the thymus [see Eqs. (10)
and (16)].
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is the rate of viral influx from blood.
Parameter estimation
The variables and parameters related to normal human thy-
mopoiesis have been defined in our previous paper.7 The ini-
tial values for infected cell populations and viral strains are all
0 to ensure the thymus initially remains uninfected before the
influx of virus from blood.Different parameter values are used
for R5 or X4 infection according to literature reports (Table 2).
Infection rates, bij (i R,X, j 1,2,3), are estimated based
on relative surface expression of coreceptor CCR5 and CXCR4
on thymocytes.16–17 As suggested in the literature, the amount
of proviral DNA detected after infection with R5 or X4 strains
is correlated with relative CCR5 or CXCR4 surface expres-
sion.16,21 Extra death rates of uninfected thymocytes, mi and ni
(i 1, 2, 3, 4, 5), are estimated based on the apoptosis rate of
thymocytes.8,30
No data exist regarding differentiation rates of infected thy-
mocytes. We speculate that HIV-1 infection impairs the matura-
tion process based on a decrease in total thymocyte number.8–10
Thus half-normal values of differentiation rates are used for the
corresponding infected thymocyte subsets, f ij (i R,X, j 1,2,3).
Similarly, we use half-normal values of emigration rates for in-
fected SP4 and SP8 cells, eij (i R,X, j 1,2). X4 strains rapidly
and efficiently kill thymocytes as compared with the R5 strains,
and infected thymocytes have higher death rates than uninfected
cells.20,66 Taking these factors into account, a 2-fold higher rate
is used for the death rate of R5-infected cells and 3-fold higher
rate is used for X4-infected cells, d ij (i  R,X, j 1,2,3,4).
Productively infected cells in the lymphoid tissue and blood
have viral RNA copy numbers in the range of 20–200 per cell.67
Mature SP4 and SP8 thymocytes are able to sustain a high level
of HIV-1 replication, while immature thymocytes produce sig-
nificantly less. This phenomenon correlates with stage-specific
activation and maturation.21,54 X4-infected cells produce more
virions than R5-infected cells.20,21 We estimate the viral pro-
duction rate for each infected thymocyte subset, p ij (i R,X, j
1,2,3,4), according to the above evidence.
No data are available regarding viral transport from blood
into the thymus. The maximal value of the rate of viral influx
we used in this model, si0 (i R,X) is estimated from our sim-
ulations (using uncertainty and sensitivity analyses). A 2-fold
higher rate of viral influx is used for children, as HIV-1 levels
in children remain high during the first 2 years of life.33 Data
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3.1/day.68 We use this same estimate for the clearance rate of
virus from the thymus, di (i R,X). Viral export from the thy-
mus, ei (i R,X), is estimated from model simulations, as no
data exist on this value.
Finally, three half-saturation constants, ci (i 1,2,3), repre-
senting the effects of HIV-1 on the cell source, TES region, and
enhanced death rates, are estimated through model simulations.
The time for the rate of viral influx to reach half-saturation
level, c4, is determined at Day 200, since clinical data indicate
that plasma viral load reaches relatively stable levels after 200
days of primary infection.65,69
Once the model equations are established together with the
values for the parameters, we solve the system of ordinary dif-
ferential equations using two appropriate numerical methods.
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TABLE 2. PARAMETER ESTIMATION IN THE MODEL OF THYMIC INFECTION WITH HIV-1
Parameter Definition Value Unit References
bR1 Infection rate of DP cells with R5 5 3 10212 /day ? virus 16–18, estimated
bR2 Infection rate of SP4 cells with R5 10212 /day ? virus 16–18, estimated
bX1 Infection rate of ITTP cells with X4 5 3 10210 /day ? virus 16–18, estimated
bX2 Infection rate of DP cells with X4 10210 /day ? virus 16–18, estimated
bX3 Infection rate of SP4 cells with X4 2 3 10211 /day ? virus 16–18, estimated
m1 Enhanced death rate of uninfected TN cells during R5 infection 0.06 /day 8,30, estimated
m2 Enhanced death rate of uninfected ITTP cells during R5 infection 0.04 /day 8,30, estimated
m3 Enhanced death rate of uninfected DP cells during R5 infection 0.2 /day 8,30, estimated
m4 Enhanced death rate of uninfected SP4 cells during R5 infection 0.11 /day 8,30, estimated
m5 Enhanced death rate of uninfected SP8 cells during R5 infection 0.03 /day 8,30, estimated
n1 Enhanced death rate of uninfected TN cells during X4 infection 0.21 /day 8,30, estimated
n2 Enhanced death rate of uninfected ITTP cells during X4 infection 0.14 /day 8,30, estimated
n3 Enhanced death rate of uninfected DP cells during X4 infection 0.33 /day 8,30, estimated
n4 Enhanced death rate of uninfected SP4 cells during X4 infection 0.26 /day 8,30, estimated
n5 Enhanced death rate of uninfected SP8 cells during X4 infection 0.03 /day 8,30, estimated
fX1 Differentiation rate of X4-infected ITTP cells into DP cells 0.25 /day Estimated
fR1(f
X
2) Differentiation rate of R5(X4)-infected DP cells into SP4 cells 0.02 /day Estimated
f R2(f
X
3) Differentiation rate of R5(X4)-infected DP cells into SP8 cells 0.01 /day Estimated
e R1(e
X
1) Emigration rate of R5(X4)-infected SP4 cells 0.04 /day Estimated
e R2(e
X
2) Emigration rate of R5(X4)-infected SP8 cells 0.04 /day Estimated
d R1 Death rate of R5-infected DP cells 0.66 /day 20,66, estimated
dR2 Death rate of R5-infected SP4 cells 0.53 /day 20,66, estimated
dR3 Death rate of R5-infected SP8 cells 0.53 /day 20,66, estimated
dX1 Death rate of X4-infected ITTP cells 0.51 /day 20,66, estimated
dX2 Death rate of X4-infected DP cells 1.00 /day 20,66, estimated
dX3 Death rate of X4-infected SP4 cells 0.79 /day 20,66, estimated
dX4 Death rate of X4-infected SP8 cells 0.79 /day 20,66, estimated
pR1 R5 production rate by R5-infected DP cells 10 Virus/cell 20,54,67
pR2 R5 production rate by R5-infected SP4 cells 100 Virus/cell 20,54,67
pR3 R5 production rate by R5-infected SP8 cells 100 Virus/cell 20,54,67
pX1 X4 production rate by X4-infected ITTP cells 20 Virus/cell 20,54,67
pX2 X4 production rate by X4-infected DP cells 20 Virus/cell 20,54,67
pX3 X4 production rate by X4-infected SP4 cells 200 Virus/cell 20,54,67
pX4 X4 production rate by X4-infected SP8 cells 200 Virus/cell 20,54,67
sR0(s
X
0) Maximum input of R5 from blood to the thymus 2 3 109 Virus/day 33, estimated
children 
109 adults Virus/day 33, estimated
dR(dX) Clearance rate of R5(X4) within the thymus 3.1 /day 68
eR(eX) Export rate of R5(X4) from the thymus to blood 100 /day Estimated
c1 Half-saturation constant, virus on cell source 106 Virus Estimated
c2 Half-saturation constant, virus on TES region 105 Virus Estimated
c3 Half-saturation constant, virus on enhanced death rate 107 Virus Estimated
c4 Half-saturation constant, time on rate of viral influx from blood 200 Day Estimated
Uncertainty and sensitivity analysis
We use Latin hypercube sampling and partial rank correla-
tion (PRC) (cf. ref. 42) for uncertainty and sensitivity analyses,
respectively. For the uncertainty analysis, a random sample of
each of the parameters to be tested is generated from a file of
parameter ranges and distributions. The sets of parameter val-
ues are randomly chosen and then used in independent simula-
tions. This provides a range of results for each solution curve
generated from the original parameter set. The sensitivity anal-
ysis is used to determine which parameter(s) have the greatest
influence on the variation in outcomes resulting from the un-
certainty analysis. By comparing coefficients of PRC, the rel-
ative importance of individual parameters can be quantitatively
evaluated.
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